Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

doi:10.1200/JCO.2011.35.0371

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jul 2011

Krönke Jan, Schlenk Richard F, Jensen Kai-Ole, Tschürtz Florian, Corbacioglu Andrea, Gaidzik Verena I, Paschka Peter, Onken Shiva, Eiwen Karina, Habdank Marianne, Späth Daniela, Lübbert Michael, Wattad Mohammed, Kindler Thomas, Salih Helmut R, Held Gerhard, Nachbaur David, von Lilienfeld-Toal Marie, Germing Ulrich, Haase Detlef, Mergenthaler Hans-Günther, Krauter Jürgen, Ganser Arnold, Göhring Gudrun, Schlegelberger Brigitte, Döhner Hartmut, Döhner Konstanze

Abstract excerpt

PURPOSE: To evaluate the prognostic value of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) with NPM1 mutation (NPM1(mut)). PATIENTS AND METHOD: RNA-based real-time quantitative polymerase chain reaction (RQ-PCR) specific for the detection of six different NPM1(mut) types was applied to 1,682 samples (bone marrow, n = 1,272; blood, n = 410) serially obtained from 245 intensively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Austria

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow

Share to Germany

Share to Leukemia, Myeloid, Acute

Share to Multivariate Analysis

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Recurrence

Source

Open in PubMed

Identifiers

PMID: 21555683
DOI: 10.1200/JCO.2011.35.0371

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.PMID 21555683Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.Semantic proximity Read ↗

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLSemantic proximity Read ↗

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.Semantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

Monitoring of minimal residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Assessment of Minimal Residual Disease in Standard-Risk AML.Semantic proximity Read ↗

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.